A wide range of applications in both clinical and consumer markets

A wide range of applications in both clinical and consumer markets, device image

A wide range of applications in both clinical and consumer markets

A wide range of applications in both clinical and consumer markets

We have taken the most successful consumer diagnostic technology and adapted it for multiple markets.

Glucose monitors are the most successful consumer diagnostic product with a $15bn market. Luas Diagnostics has re-engineered the sensor used in glucose monitors and applied it to detect a wide range of analytes.

Glucose monitors are the most successful consumer diagnostic product with a $15bn market. Luas Diagnostics has re-engineered the sensor used in glucose monitors and applied it to detect a wide range of analytes.

Therapeutic Drug Monitoring

Covid-19 rapid testing

Therapeutic Drug Monitoring (TDM) Test Market

Luas Diagnostics has a range of tests in development to support the Therapeutic Drug Monitoring Test (TDM) market.

TDM is the measurement of specific drugs in a patient’s bloodstream at selected intervals to help optimise individual dosing regimens.

TDM is mainly used for monitoring drugs with a narrow therapeutic range, drugs with variable absorption rates, medications for which target concentrations are difficult to monitor and drugs that can cause adverse effects. TDM aims to validate and optimise appropriate concentrations of difficult-to-manage medications to enable the assessment of the efficacy and safety of the medication in a variety of clinical environments.

$ 0 billion

Global Therapeutic TDM test market in 2018

$ 0 billion

Estimated market value by 2024

0 %

Compound Annual Growth Rate

3 tests in the pipeline

We are currently developing tests to monitor therapeutic drugs for bipolar disorder and COPD and a third test to assess the efficacy of anticoagulant therapy

Currently in development

Lithium

Treatment of bipolar disorder and schizophrenia

Global testing market $107m (c.10m tests p.a.)

2.4 million prescriptions each year in US

Theophylline

Respiratory disease, COPD, asthma

Global testing market $51m (c.8m tests p.a.)

Future Pipeline

PT-INR
(Prothrombin International Normalised Ratio)

Blood coagulation, liver function, anticoagulant medication monitoring

TDM Testing Pathway

Current Pathway - greater than 1 week

Patient arranges appointment with Doctor icon

Patient arranges appointment with Doctor

Blood sample is taken at appointment icon

Blood sample is taken at appointment

Sample sent to central lab for testing icon

Sample sent to central lab for testing

Test performed at central lab icon

Test performed at central lab

Doctor receives results and new appointment made with patient icon

Doctor receives results and new appointment made with patient

Medication adjusted icon

Medication adjusted

Luas Diagnostics' Pathway - under 24 hours

Patient Choice icon
Doctor icon

Doctor

Pharmacy icon

Pharmacy

Home icon
Simple finger-stick test performed immediately icon
If remote, results sent via smart phone for analysis icon
Doctors review results on secure servers icon
Immediate adjustment of medication icon

Patient Choice

Home

Simple finger-stick test performed immediately

If remote, results sent via smart phone for analysis

Doctors review results on secure servers

Immediate adjustment of medication

3 Patient Choices

Doctor icon

1) Doctor

Pharmacy icon

2) Pharmacy

Home icon

3) Home

Simple finger-stick test performed immediately icon

Simple finger-stick test performed immediately

If remote, results sent via smart phone for analysis icon

If remote, results sent via smart phone for analysis

Doctors review results on secure servers icon

If remote, results sent via smart phone for analysis

Immediate adjustment of medication icon

Immediate adjustment of medication

The Luas Diagnostics pathway is significantly quicker than the current traditional pathway enabling clinicians to monitor and adjust a patient’s medication within 24 hours.

Covid-19 rapid testing

Covid-19 rapid testing, virus image
Covid-19 rapid testing, virus image

The containment of the spread of Covid-19 (SARS-CoV-2) infection requires extensive testing followed by tracing of contacts of those who test positive. Reducing the turnaround time from the taking of the sample to the reporting of the result will expedite this process.

Conducting rapid testing in locations such as airports, care-homes, workplaces, clinics and drive-through testing centres and not in large laboratory settings where the turnaround time may be days, will enable results to be reported immediately, accelerating contact tracing and patient isolation, reducing further spread of infection.

Luas Diagnostics is collaborating with the Department of Biotechnology in the University of Birmingham to develop an electrochemistry-based Covid-19 antigen test using saliva rather than a nasopharyngeal swab sample. Recent studies have shown that saliva samples are more accurate than the use of nasopharyngeal swabs in the detection of the virus.

The goal is to develop a highly accurate test for Covid-19 to be used in remote settings and providing results in minutes.

Life threatening infectious diseases

Luas Diagnostics is launching an exciting range of rapid, accurate and easy to use products for life threatening infectious diseases, including Covid-19 (SARS-Cov-2) antibody and antigen tests.

The products, which are FDA and CE-IVD approved, are developed and manufactured by Chembio Diagnostic Systems Inc of Medford, New York and will be sold exclusively by Luas Diagnostics in the UK and Ireland.